Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Veronika Pozharskaya et al.|Advances in Therapy|2025Cited by 4
POSTER: MDS-730 Overall Survival (OS) and Duration of Red Blood Cell-Transfusion Independence (RBC-TI) for First-Line Erythropoiesis-Stimulating Agent (ESA)-Naïve Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept (LUSPA) vs Epoetin Alfa (EA) in the COMMANDS TrialGuillermo Garcia‐Manero, Valeria Santini, Matteo Della Porta et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0